EVALUATION OF ANALGESIC (IN VIVO) ACTIVITY OF ARIFLEX TABLET IN COMPARISON WITH DICLOFENAC AND ACECLOFENAC USING ACETIC ACID INDUCED WRITHING MODEL IN MICE

Objective: The present study was conducted to evaluate analgesic activity of Ariflex Tablet which is a polyherbal formulation conceptualized and developed by Ari Healthcare Private in comparison to Aceclofenac and Diclofenac Tablet. Methods: Albino mice of either sex weighing 20–25 g were taken and divided into four groups with six animals in each group. Group 1 (Controlled Group) animals were starved overnight. Group 2 animals were orally administered with Diclofenac Tablet as Standard drug. Group 3 animals were orally administered with Aceclofenac Tablet as Standard drug and Group 4 Animals were orally administered with Ariflex Tablet. The test and standard drugs were orally administered with feeding needle after 1 h of injecting 1% acetic acid intraperitoneally in volume of 0.1 ml/10 g body weight. Writhing episodes were recorded for 30 min by counting the stretching. Results: All the tested formulations possess analgesic activity in acetic acid induced writhing model. Aceclofenac possesses strong analgesic activity compared to other formulations tested. In Ariflex Tablet Group, the number of writhes was 120.6±41.4. If compared to control group, the number of writhes was significantly less suggesting analgesic activity of Ariflex Tablet. Analgesic activity of Ariflex Tablet was close to that of Diclofenac Sodium. Conclusion: It can be concluded that Ariflex Tablet possesses significant analgesic activity. Ariflex Tablet can be used in the management of Osteoarthritis, Rheumatoid arthritis, Gouty arthritis, Lumbago, Sciatica, and Spondylitis

Simultaneous estimation of amlodipine besilate and olmesartan medoxomil in pharmaceutical dosage form

Two UV Spectrophotometric and one reverse phase high performance liquid chromatography methods have been developed for the simultaneous estimation of amlodipine besilate and olmesartan medoxomil in tablet dosage form. First UV spectrophotometric method was a determination using the simultaneous equation method at 237.5 nm and 255.5 nm over the concentration range 10-50 μg/ml and 10-50 μg/ml, for amlodipine besilate and olmesartan medoxomil with accuracy 100.09%, and 100.22% respectively. Second UV spectrophotometric method was a determination using the area under curve method at 242.5-232.5 nm and 260.5-250.5 nm over the concentration range of 10-50 μg/ml and 10-50 μg/ml, for amlodipine besilate and olmesartan medoxomil with accuracy 100.10%, and 100.48%, respectively. In reverse phase high performance liquid chromatography analysis carried out using 0.05M potassuim dihydrogen phosphate buffer:acetonitrile (50:50 v/v) as the mobile phase and Kromasil C18 (4.6 mm i.d.×250 mm) column as the stationery phase with detection wavelength of 238 nm. Flow rate was 1.0 ml/min. Retention time for amlodipine besilate and olmesartan medoxomil were 3.69 and 5.36 min, respectively. Linearity was obtained in the concentration range of 4-20 μg/ml and 10-50 μg/ml for amlodipine besilate and olmesartan medoxomil, respectively. Proposed methods can be used for the estimation of amlodipine besilate and olmesartan medoxomil in tablet dosage form provided all the validation parameters are met